Scenarios that move ARWR
Arrowhead Pharmaceuticals, Inc. - Common Stock
Scenarios that move ARWR: 5 analyses, 2 positive, 3 negative.
- · Viking Therapeutics advances oral obesity drug to Phase III — ▲ · impact +28 · confidence low · horizon quarters
- · Novartis acquires Abogen in $7.8B RNA therapeutics deal — ▲ · impact +38 · confidence low · horizon weeks
- · ADARx Pharmaceuticals prices upsized $446.3 million initial public offering — ▼ · impact -32 · confidence low · horizon quarters
- · Ionis reports positive late-stage results for two partnered drugs — ▼ · impact -60 · confidence low · horizon immediate
- · Amgen shares fall after Novartis' Pelacarsen misses Phase III goal — ▼ · impact -20 · confidence low · horizon quarters